Cardiol Therapeutics Inc. reported nine-month net loss of 30,225,020 and cash and cash equivalents of 29,229,802 at September 30, 2026. It established a US$75,000,000 ATM program with Jefferies LLC and raised US$4.55 million afterward.
CRDL · Cardiol Therapeutics Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Latest documents
Cardiol Therapeutics Inc. agreed with Jefferies LLC to issue and sell common shares with an aggregate offering price of up to US$75,000,000.
Cardiol Therapeutics Inc. entered an agreement with Jefferies LLC to offer and sell up to US$75 million under an at-the-market program. The company has no obligation to sell any shares, and proceeds would support CardiolRx and CRD-38 development.
Cardiol Therapeutics Inc. reached 110-patient MAVERIC enrollment target ahead of schedule and plans expansion to up to 150 patients after fewer-than-expected recurrences. Topline results are anticipated in mid-2027, versus previous Q1 2027 guidance; cash runway extends into Q1 2028.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRDL
this stock
Cardiol Therapeutics Inc.
|
$112.71M | -7.5% | — | — | 2.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.40B | +37.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$51.90B | +7.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$44.97B | +23.5% | +4.3% | 87.6 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 35
Cardiol Therapeutics Inc. reported nine-month net loss of 30,225,020 and cash and cash equivalents of 29,229,802 at September 30, 2026. It established a US$75,000,000 ATM program with Jefferies LLC and raised US$4.55 million afterward.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRDL | -15.1% | -23.2% | -27.7% | -20.5% | -7.5% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -9.7% | -17.0% | -22.0% | -15.2% | -12.5% |